Anti-nociceptive effects of Tanshinone IIA (TIIA) in a rat model of complete Freund's adjuvant (CFA)-induced inflammatory pain

Brain Research Bulletin

Volumn 88, Issue 6, 2012, Pages 581-588

  Sun, Shukai ^a   Yin, Yue ^b   Yin, Xin ^b   Cao, Fale ^c   Luo, Daoshu ^a,d   Zhang, Ting ^a   Li, Yunqing ^a   Ni, Longxing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c Department of Respiration and Neurology   (China)

^d FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

CFA; ERK; Inflammatory pain; Tanshinone IIA; TRPV1

Indexed keywords

ANTINOCICEPTIVE AGENT; FREUND ADJUVANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; TANSHINONE IIA; TUMOR NECROSIS FACTOR ALPHA; VANILLOID RECEPTOR 1;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GANGLION; HYPERSENSITIVITY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY PAIN; LATENT PERIOD; LUMBAR SPINAL CORD; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; THERMAL STIMULATION; WESTERN BLOTTING;

ANALGESICS, NON-NARCOTIC; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CYTOKINES; DITERPENES, ABIETANE; DRUG EVALUATION, PRECLINICAL; DRUGS, CHINESE HERBAL; FREUND'S ADJUVANT; GANGLIA, SPINAL; GENE EXPRESSION REGULATION; HOT TEMPERATURE; HYPERALGESIA; LUMBOSACRAL REGION; MALE; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SINGLE-BLIND METHOD; STRESS, MECHANICAL; TRPV CATION CHANNELS;

EID: 84864091390     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2012.06.002     Document Type: Article

References (55)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anatomical Record 1946, 94:239-247.
2. Adwanikar H., Karim F., Gereau R.Wt Inflammation persistently enhances nocifensive behaviors mediated by spinal group I mGluRs through sustained ERK activation. Pain 2004, 111:125-135.
3. Bai A., Lu N., Guo Y., Fan X. Tanshinone IIA ameliorates trinitrobenzene sulfonic acid (TNBS)-induced murine colitis. Digestive Diseases and Sciences 2008, 53:421-428.
4. Calixto J.B., Otuki M.F., Santos A.R. Anti-inflammatory compounds of plant origin. Part I. Action on arachidonic acid pathway, nitric oxide and nuclear factor kappa B (NF-kappaB). Planta Medica 2003, 69:973-983.
5. Calixto J.B., Campos M.M., Otuki M.F., Santos A.R. Anti-inflammatory compounds of plant origin. Part II. Modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Medica 2004, 70:93-103.
6. Carlton S.M., Coggeshall R.E. Peripheral capsaicin receptors increase in the inflamed rat hindpaw: a possible mechanism for peripheral sensitization. Neuroscience Letters 2001, 310:53-56.
7. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
8. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Trafton J., et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000, 288:306-313.
9. Choi H.S., Cho D.I., Choi H.K., Im S.Y., Ryu S.Y., et al. Molecular mechanisms of inhibitory activities of tanshinones on lipopolysaccharide-induced nitric oxide generation in RAW 264.7 cells. Archives of Pharmacal Research 2004, 27:1233-1237.
10. Cortright D.N., Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV1. An update. European Journal of Biochemistry 2004, 271:1814-1819.
11. Cunha F.Q., Poole S., Lorenzetti B.B., Ferreira S.H. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. British Journal of Pharmacology 1992, 107:660-664.
12. Cunha T.M., Verri W.A., Silva J.S., Poole S., Cunha F.Q., et al. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:1755-1760.
13. Davis J.B., Gray J., Gunthorpe M.J., Hatcher J.P., Davey P.T., et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000, 405:183-187.
14. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
15. Dong X., Dong J., Zhang R., Fan L., Liu L., et al. Anti-inflammatory effects of tanshinone IIA on radiation-induced microglia BV-2 cells inflammatory response. Cancer Biotherapy and Radiopharmaceuticals 2009, 24:681-687.
16. Dube G.R., Elagoz A., Mangat H. Acid sensing ion channels and acid nociception. Current Pharmaceutical Design 2009, 15:1750-1766.
17. Ferreira S.H., Lorenzetti B.B., Bristow A.F., Poole S. Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 1988, 334:698-700.
18. Galan A., Cervero F., Laird J.M. Extracellular signaling-regulated kinase-1 and -2 (ERK 1/2) mediate referred hyperalgesia in a murine model of visceral pain. Brain Research. Molecular Brain Research 2003, 116:126-134.
19. Guillery R.W. On counting and counting errors. Journal of Comparative Neurology 2002, 447:1-7.
20. Hayes P., Meadows H.J., Gunthorpe M.J., Harries M.H., Duckworth D.M., et al. Cloning and functional expression of a human orthologue of rat vanilloid receptor-1. Pain 2000, 88:205-215.
21. Hensellek S., Brell P., Schaible H.G., Brauer R., Segond von Banchet G. The cytokine TNFalpha increases the proportion of DRG neurones expressing the TRPV1 receptor via the TNFR1 receptor and ERK activation. Molecular and Cellular Neurosciences 2007, 36:381-391.
22. Huang J., Zhang X., McNaughton P.A. Inflammatory pain: the cellular basis of heat hyperalgesia. Current Neuropharmacology 2006, 4:197-206.
23. Hylden J.L., Nahin R.L., Traub R.J., Dubner R. Expansion of receptive fields of spinal lamina I projection neurons in rats with unilateral adjuvant-induced inflammation: the contribution of dorsal horn mechanisms. Pain 1989, 37:229-243.
24. Iadarola M.J., Brady L.S., Draisci G., Dubner R. Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding. Pain 1988, 35:313-326.
25. Jang S.I., Jeong S.I., Kim K.J., Kim H.J., Yu H.H., et al. Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide synthase expression and production of TNF-alpha, IL-1beta and IL-6 in activated RAW 264.7 cells. Planta Medica 2003, 69:1057-1059.
26. Jang S.I., Kim H.J., Kim Y.J., Jeong S.I., You Y.O. Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. European Journal of Pharmacology 2006, 542:1-7.
27. Ji R.R. Mitogen-activated protein kinases as potential targets for pain killers. Current Opinion in Investigational Drugs 2004, 5:71-75.
28. Ji R.R., Woolf C.J. Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiology of Disease 2001, 8:1-10.
29. Ji R.R., Samad T.A., Jin S.X., Schmoll R., Woolf C.J. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002, 36:57-68.
30. Jin S.X., Zhuang Z.Y., Woolf C.J., Ji R.R. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. Journal of Neuroscience 2003, 23:4017-4022.
31. Kanai Y., Hara T., Imai A., Sakakibara A. Differential involvement of TRPV1 receptors at the central and peripheral nerves in CFA-induced mechanical and thermal hyperalgesia. Journal of Pharmacy and Pharmacology 2007, 59:733-738.
32. Kang B.Y., Chung S.W., Kim S.H., Ryu S.Y., Kim T.S. Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from Salvia miltiorrhiza. Immunopharmacology 2000, 49:355-361.
33. Karim F., Hu H.J., Adwanikar H., Kaplan D., Gereau R.Wt. Impaired inflammatory pain and thermal hyperalgesia in mice expressing neuron-specific dominant negative mitogen activated protein kinase kinase (MEK). Molecular Pain 2006, 2:2.
34. Kawasaki Y., Kohno T., Zhuang Z.Y., Brenner G.J., Wang H., et al. Ionotropic and metabotropic receptors, protein kinase A, protein kinase C, and Src contribute to C-fiber-induced ERK activation and cAMP response element-binding protein phosphorylation in dorsal horn neurons, leading to central sensitization. Journal of Neuroscience 2004, 24:8310-8321.
35. Kidd B.L., Urban L.A. Mechanisms of inflammatory pain. British Journal of Anaesthesia 2001, 87:3-11.
36. Kiguchi N., Maeda T., Kobayashi Y., Saika F., Kishioka S. Involvement of inflammatory mediators in neuropathic pain caused by vincristine. International Review of Neurobiology 2009, 85:179-190.
37. Kym P.R., Kort M.E., Hutchins C.W. Analgesic potential of TRPV1 antagonists. Biochemical Pharmacology 2009, 78:211-216.
38. Li W., Li J., Ashok M., Wu R., Chen D., et al. A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. Journal of Immunology 2007, 178:3856-3864.
39. Luo H., Cheng J., Han J.S., Wan Y. Change of vanilloid receptor 1 expression in dorsal root ganglion and spinal dorsal horn during inflammatory nociception induced by complete Freund's adjuvant in rats. Neuroreport 2004, 15:655-658.
40. McIntyre P., McLatchie L.M., Chambers A., Phillips E., Clarke M., et al. Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). British Journal of Pharmacology 2001, 132:1084-1094.
41. Mendell J.R., Sahenk Z. Clinical practice. Painful sensory neuropathy. New England Journal of Medicine 2003, 348:1243-1255.
42. Milligan E.D., Mehmert K.K., Hinde J.L., Harvey L.O., Martin D., et al. Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120. Brain Research 2000, 861:105-116.
43. Minami M., Katayama T., Satoh M. Brain cytokines and chemokines: roles in ischemic injury and pain. Journal of Pharmacological Sciences 2006, 100:461-470.
44. Miyamoto R., Tokuda M., Sakuta T., Nagaoka S., Torii M. Expression and characterization of vanilloid receptor subtype 1 in human dental pulp cell cultures. Journal of Endodontics 2005, 31:652-658.
45. Pitcher M.H., Price T.J., Entrena J.M., Cervero F. Spinal NKCC1 blockade inhibits TRPV1-dependent referred allodynia. Molecular Pain 2007, 3:17.
46. Schottelius A.J., Mayo M.W., Sartor R.B., Baldwin A.S. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. Journal of Biological Chemistry 1999, 274:31868-31874.
47. Simao da Silva K.A., Paszcuk A.F., Passos G.F., Silva E.S., Bento A.F., et al. Activation of cannabinoid receptors by the pentacyclic triterpene alpha, beta-amyrin inhibits inflammatory and neuropathic persistent pain in mice. Pain 2011, 152:1872-1887.
48. Svensson C.I., Hua X.Y., Protter A.A., Powell H.C., Yaksh T.L. Spinal p38 MAP kinase is necessary for NMDA-induced spinal PGE(2) release and thermal hyperalgesia. Neuroreport 2003, 14:1153-1157.
49. Tang L., Chen Y., Chen Z., Blumberg P.M., Kozikowski A.P., et al. Antinociceptive pharmacology of N-(4-chlorobenzyl)-N'-(4-hydroxy-3-iodo-5-methoxybenzyl) thiourea, a high-affinity competitive antagonist of the transient receptor potential vanilloid 1 receptor. Journal of Pharmacology and Experimental Therapeutics 2007, 321:791-798.
50. van Deuren M., Netea M.G., Hijmans A., Demacker P.N., Neeleman C., et al. Posttranscriptional down-regulation of tumor necrosis factor-alpha and interleukin-1beta production in acute meningococcal infections. Journal of Infectious Diseases 1998, 177:1401-1405.
51. Verri W.A., Cunha T.M., Parada C.A., Poole S., Cunha F.Q., et al. Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development?. Pharmacology & Therapeutics 2006, 112:116-138.
52. Wang Z.Q., Wu D.C., Huang F.P., Yang G.Y. Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia. Brain Research 2004, 996:55-66.
53. Zhou L., Zuo Z., Chow M.S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. Journal of Clinical Pharmacology 2005, 45:1345-1359.
54. Zhuang Z.Y., Xu H., Clapham D.E., Ji R.R. Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. Journal of Neuroscience 2004, 24:8300-8309.
55. Zhuang Z.Y., Gerner P., Woolf C.J., Ji R.R. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005, 114:149-159.